Dec 09, 2025 8:00am EST Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Dec 02, 2025 8:00am EST Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Nov 20, 2025 8:00am EST Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Nov 17, 2025 8:05am EST Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Sep 04, 2025 8:00am EDT Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Aug 19, 2025 8:00am EDT Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Aug 13, 2025 4:15pm EDT Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Jul 31, 2025 8:00am EDT Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback